- $504.78m
- -$62.82m
- $262.60m
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
U.S. RESEARCH ROUNDUP-Air Products, Amgen, Duolingo
Arvinas Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Arvinas To Reduce Workforce By Approximately 33% - SEC Filing
U.S. RESEARCH ROUNDUP-Aerovironment, Apple, Starbucks
Arvinas hits all-time low following Piper Sandler PT cut
U.S. RESEARCH ROUNDUP-Apple, Tesla, Walmart
U.S. STOCKS ON THE MOVE-Super Micro Computer, FedEx, US airlines
Arvinas falls after Leerink's price target cut
U.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney
U.S. STOCKS ON THE MOVE-BankUnited, Hesai Group, Sezzle
Arvinas hits all-time low after breast cancer drug trial results
U.S. STOCKS ON THE MOVE-Primo Brands, Exxon, FB Financial
Arvinas plummets after late-stage data from breast cancer treatment
Pfizer-Arvinas' breast cancer treatment cuts progression for some patients in study (updated)
Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study
Brief: Arvinas And Pfizer Announce Positive Topline Results From Phase 3 Veritac-2 Clinical Trial
Arvinas Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Arvinas Q4 Basic EPS USD -0.63 Vs. IBES Estimate USD -1.02